Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane
- 8 April 2022
- journal article
- research article
- Published by Elsevier in Acta Biomaterialia
- Vol. 145, 246-259
Abstract
No abstract availableKeywords
Funding Information
- China Postdoctoral Science Foundation (2021M693135)
- Natural Science Foundation of Zhejiang Province (LY20H080002, LY20H080004)
- National Natural Science Foundation of China (81971991)
This publication has 42 references indexed in Scilit:
- ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not plateletsBritish Journal of Haematology, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- Traveling Bax and Forth from Mitochondria to Control ApoptosisCell, 2011
- Constructing doxorubicin-loaded polymeric micelles through amphiphilic graft polyphosphazenes containing ethyl tryptophan and PEG segmentsActa Biomaterialia, 2009
- Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53Blood, 2006
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006
- Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cδ–dependent mechanismsBlood, 2005
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocationCell, 1986
- Involvement of the bcl -2 Gene in Human Follicular LymphomaScience, 1985